Periowave(TM) Gum Disease Treatment Studies to be Presented at AADR Annual Meeting

    VANCOUVER, March 27 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM:
OBP; the "Company"), a medical technology company developing
photodisinfection-based products, today announced that the results of two
studies using the Periowave(TM) Photodisinfection System will be presented at
the American Association for Dental Research (AADR) Annual Meeting, April 2-6,
2008 in Dallas, Texas. The studies provide evidence of the safety and efficacy
of Periowave(TM) as a treatment for periodontal diseases.
    The first study examined the use of Periowave(TM) on dental implants.
This study showed that Periowave(TM) treatment of the surfaces of dental
implants effectively eradicated dense biofilms of the oral bacterium
Porphyromonas gingivalis, without altering surface metal chemistry of the
implant. Periopathogens like P. gingivalis are often responsible for failures
of these implants, resulting in costly reparative procedures. The second
abstract discussed the previously announced meta-analysis of three clinical
trials utilizing the Periowave(TM) Photodisinfection System for the treatment
of chronic periodontitis.
    "The inclusion of our abstracts in this year's AADR meeting is an
important accomplishment for our Company as it reflects the high quality of
research and the dental community's interest in our Photodisinfection
technology," said Carolyn Cross, President & CEO of Ondine Biopharma.
    The following two abstracts are scheduled to be presented:

    Abstract: 0942
    Periowave eradicates biofilms from dental implants without altering
    surface chemistry
    R.J. Scott et al., Ondine Research Laboratories, Bothell WA

    Abstract: 1222
    Meta-Analysis of Three Chronic Periodontitis Trials with Periowave(TM)
    N.G. Loebel, et al., Ondine Research Laboratories, Bothell, WA, USA,

    The text of the abstracts and additional information on AADR can be found

    About Periowave(TM)

    Periowave(TM) is a photodisinfection system commercialized by Ondine that
utilizes low-intensity lasers and microbiological stains to target and destroy
microbial pathogens and reduce the symptoms of disease. The photodisinfection
technology was developed by Professor Michael Wilson and colleagues at the
Eastman Dental Institute, University College London, and licensed to Ondine by
UCL Business plc, University College London. Periowave(TM) is currently
approved in Canada and the European Union for several oral indications.
Additional information about Periowave(TM) is available at

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is headquartered in Vancouver, British
Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and
an international office in St. Michael, Barbados. For additional information,
please visit the Company's website at:

    Forward-Looking Statements:

    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

    The TSX Exchange has not reviewed and does not accept responsibility for
    the adequacy or accuracy of this release.

For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269,; Irma
Gomez-Dib, Media & Investor Relations, FD, (212) 850-5761,; Canaccord Adams Ltd, Nominated Adviser & Broker, Neil
Johnson, Ryan Gaffney, +4420 7050 6500

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890